MedTrace Logo

Development Platform Construction and Application Promotion of Drug-Eluting Stents for Intracranial Aneurysm Interventional Therapy

NCT07190781 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2025-09-24

No results posted yet for this study

Summary

This study is a post-marketing clinical study of the Lattice Flow-Diverting Dense-Mesh Stent. It plans to enroll 280 patients, who will be treated for unruptured intracranial aneurysms using the Lattice Flow-Diverting Dense-Mesh Stent. Patients will be followed up at 12 months after device implantation, and data including the Raymond classification of the target aneurysms, the occurrence of complications, and whether complications result in neurological deficit symptoms will be collected and assessed. Through the above indicators, the clinical safety and efficacy of the product will be evaluated.

Conditions

  • Cerebral Aneurysm Unruptured

Interventions

DEVICE

Flow-Diverting Dense-Mesh Stent

Surface-Modified Flow-Diverting Dense-Mesh Stent for Mid-Term Follow-Up Study of Endovascular Embolization Therapy for Cerebral Aneurysms

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Beijing Chao Yang Hospital

    collaborator OTHER

  • Peking University International Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Xinjian Yang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2022-10-24
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07190781 on ClinicalTrials.gov